Physician profile
Michael Boyd
NPI 1538107818
$4,856.77
in general payments reported to CMS, 2019-2025
16 companies · $551 in 2025
The $551 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $2,816 · 2021: $66.04 · 2022: $16.20 · 2023: $104 · 2024: $357 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $2,815.94 | 2020 | |
| Stryker Corporation | $1,435.12 | 2019-2025 | Mako, Triathlon |
| Linkbio Corp | $271.38 | 2024 | |
| Ethicon US, LLC | $55.12 | 2025 | Dermabond Prineo, Stratafix, Evarrest |
| Biocomposites INC | $45.45 | 2021 | |
| Depuy Synthes Sales INC. | $37.44 | 2023 | Inhance |
| Djo, LLC | $32.28 | 2023 | Donjoy |
| Amgen INC. | $24.77 | 2019 | |
| Innovation Technologies INC | $24.16 | 2025 | Irrisept |
| Ferring Pharmaceuticals INC. | $23.20 | 2025 | Euflexxa |
| Sanofi-Aventis U.S. LLC | $20.04 | 2023 | |
| Orthogenrx INC. | $17.16 | 2019 | |
| Orthofix Medical, INC. | $16.20 | 2022 | |
| Smith+Nephew, INC. | $14.49 | 2023 | Journey II |
| Endo Pharmaceuticals INC. | $12.92 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.